
Lyme Disease - Pipeline Insight, 2024
Description
Lyme Disease - Pipeline Insight, 2024
DelveInsight’s, “Lyme Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lyme Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Lyme Disease: Overview
Lyme disease is the most common vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.
""Lyme Disease - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lyme Disease pipeline landscape is provided which includes the disease overview and Lyme Disease treatment guidelines. The assessment part of the report embraces, in depth Lyme Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lyme Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lyme Disease R&D. The therapies under development are focused on novel approaches to treat/improve Lyme Disease.
This segment of the Lyme Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lyme Disease Emerging Drugs
- VLA 15: Valneva
- CT38: Cortene
Further product details are provided in the report……..
Lyme Disease: Therapeutic Assessment
This segment of the report provides insights about the different Lyme Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Lyme Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Lyme Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lyme Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lyme Disease drugs.
Lyme Disease Report Insights
- Lyme Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lyme Disease drugs?
- How many Lyme Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lyme Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lyme Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lyme Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Valneva
- Cortene
- Blue Lake Biotechnology
- Tarsus Pharmaceuticals
- Inovio Pharmaceuticals
- Aegis Life
- Abzyme Therapeutics
- VLA 15
- CT38
- BLB 400
- AB 007
- Research programme: DNA-based monoclonal antibody therapeutics
- Lotilaner
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Lyme Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Lyme Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- VLA 15: Valneva
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CT 38: Cortene
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Lyme disease vaccine - Introvacc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Lyme Disease Key Companies
- Lyme Disease Key Products
- Lyme Disease- Unmet Needs
- Lyme Disease- Market Drivers and Barriers
- Lyme Disease- Future Perspectives and Conclusion
- Lyme Disease Analyst Views
- Lyme Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.